Now Playing
Opinion|Videos|October 13, 2023
Evolving Treatment Strategies in HER2-Positive Early Breast Cancer
Author(s)Sandra M. Swain, MD, FACP, FASCO
Sandra M. Swain, MD, FACP, FASCO, reviews clinical trial data and how they inform the evolving treatment landscape in HER2+ early breast cancer.
Advertisement
Advertisement
Related to this article
Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
More than 76% of US counties have no TNBC trial, and only 9.8% of rural counties have one vs 47% of metropolitan counties, a new analysis finds.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5